Cargando…

Effects of ABCB1, UGT1A1, and UGT1A9 Genetic Polymorphisms on the Pharmacokinetics of Sitafloxacin Granules in Healthy Subjects

Sitafloxacin, a new fluoroquinolone, has strong antibacterial activity. We evaluated the effects of sitafloxacin granules in single‐dose and multidose cohorts and the effects of ABCB1, UGT1A1, and UGT1A9 genetic polymorphisms on the pharmacokinetics (PK) of sitafloxacin in healthy subjects. The sing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Lu‐Ning, Sun, Guo‐Xian, Yang, Yu‐Qing, Shen, Ye, Huang, Feng‐Ru, Xie, Li‐Jun, Cheng, Juan, Zhang, Hong‐Wen, Zhang, Xue‐Hui, Liu, Yun, Wang, Yong‐Qing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818398/ https://www.ncbi.nlm.nih.gov/pubmed/32687695 http://dx.doi.org/10.1002/cpdd.848

Ejemplares similares

Differences in UGT1A1, UGT1A7, and UGT1A9 Polymorphisms between Uzbek and Japanese Populations
por: Maeda, Hiromichi, et al.
Publicado: (2014)

Profiling of UGT1A1(*)6, UGT1A1(*)60, UGT1A1(*)93, and UGT1A1(*)28 Polymorphisms in Indonesian Neonates With Hyperbilirubinemia Using Multiplex PCR Sequencing
por: Amandito, Radhian, et al.
Publicado: (2019)

Polymorphisms of UGT1A1(*)6, UGT1A1(*)27 & UGT1A1(*)28 in three major ethnic groups from Malaysia
por: Teh, L. K., et al.
Publicado: (2012)

Commentary: Profiling of UGT1A1(*)6, UGT1A1(*)60, UGT1A1(*)93, and UGT1A1(*)28 Polymorphisms in Indonesian Neonates With Hyperbilirubinemia Using Multiplex PCR Sequencing
por: Heydari, Mohammad Reza, et al.
Publicado: (2020)

UGT1A1 and UGT1A9 Are Responsible for Phase II Metabolism of Tectorigenin and Irigenin In Vitro
por: Li, Ji, et al.
Publicado: (2022)

Genotyping of UGT1A1*80 as an Alternative to UGT1A1*28 Genotyping in Spain
por: Bravo-Gómez, Adrián, et al.
Publicado: (2022)

Association of gallstone and polymorphisms of UGT1A1*27 and UGT1A1*28 in patients with hepatitis B virus-related liver failure
por: Zhuo, Haiyan, et al.
Publicado: (2022)

Relationship between UGT1A1*27 and UGT1A1*7 polymorphisms and irinotecan‐related toxicities in patients with lung cancer
por: Fukuda, Minoru, et al.
Publicado: (2017)

Evaluation of the effect of UGT1A1 polymorphisms on the pharmacokinetics of oral and long-acting injectable cabotegravir
por: Patel, Parul, et al.
Publicado: (2020)

UGT1A1 polymorphisms in cancer: impact on irinotecan treatment
por: Takano, Masashi, et al.
Publicado: (2017)

Association of UGT2B7 and UGT1A4 Polymorphisms with Serum Concentration of Antiepileptic Drugs in Children
por: Du, Zhongliang, et al.
Publicado: (2016)

Epigenetics and microRNAs in UGT1As
por: Meng, Cui-Lan, et al.
Publicado: (2021)

Impact of polymorphisms in CYP and UGT enzymes and ABC and SLCO1B1 transporters on the pharmacokinetics and safety of desvenlafaxine
por: Calleja, Sofía, et al.
Publicado: (2023)

Impact of UGT1A9 Polymorphism on Mycophenolic Acid Pharmacokinetic Parameters in Stable Renal Transplant Patients
por: Mazidi, Talia, et al.
Publicado: (2013)

The Impact of ABCB1 and CES1 Polymorphisms on Dabigatran Pharmacokinetics in Healthy Chinese Subjects
por: Liu, Yue, et al.
Publicado: (2021)

Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients
por: Romero-Lorca, Alicia, et al.
Publicado: (2015)

Association of Neonatal Hyperbilirubinemia with UGT1A1 Gene Polymorphisms: A Meta-Analysis
por: Yu, Zibi, et al.
Publicado: (2015)

Correction: Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients
Publicado: (2015)

Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 Study
por: Seneviratne, Herana Kamal, et al.
Publicado: (2021)

Polymorphisms of estrogen metabolism-related genes ESR1, UGT2B17, and UGT1A1 are not associated with osteoporosis in surgically menopausal Japanese women
por: Yokota, Megumi, et al.
Publicado: (2015)

Lack of UGT polymorphism association with idasanutlin pharmacokinetics in solid tumor patients
por: So, W. Venus, et al.
Publicado: (2018)

Postoperative jaundice related to UGT1A1 and ABCB11 gene mutations: A case report and literature review
por: Jiang, Jin-Lian, et al.
Publicado: (2023)

Correction to “Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 Study”
por: Seneviratne, Herana Kamal, et al.
Publicado: (2021)

The association of genetic polymorphisms in CYP1A2, UGT1A4, and ABCB1 with autonomic nervous system dysfunction in schizophrenia patients treated with olanzapine
por: Hattori, Saki, et al.
Publicado: (2020)

Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism
por: Xu, C-F, et al.
Publicado: (2010)

Distribution of selected gene polymorphisms of UGT1A1 in a Saudi population
por: Alkharfy, Khalid M., et al.
Publicado: (2013)

Predictive Value of UGT1A1*28 Polymorphism In Irinotecan-based Chemotherapy
por: Liu, Xing-Han, et al.
Publicado: (2017)

The association between UGT1A1 polymorphisms and treatment toxicities of liposomal irinotecan
por: Su, Y.-Y., et al.
Publicado: (2022)

Characteristics and Clinical Implication of UGT1A1 Heterozygous Mutation in Tumor
por: LI, Qian, et al.
Publicado: (2022)

Complete Reaction Phenotyping of Propranolol and 4-Hydroxypropranolol with the 19 Enzymes of the Human UGT1 and UGT2 Families
por: Yang, Fan, et al.
Publicado: (2022)

Meta‐Analysis of Noncompartmental Pharmacokinetic Parameters of Ertugliflozin to Evaluate Dose Proportionality and UGT1A9 Polymorphism Effect on Exposure
por: Marshall, Jean‐Claude, et al.
Publicado: (2021)

Common UGT1A6 Variant Alleles Determine Acetaminophen Pharmacokinetics in Man
por: Cerezo-Arias, María de las Olas, et al.
Publicado: (2022)

Establishment of UGT1A1-knockout human iPS-derived hepatic organoids for UGT1A1-specific kinetics and toxicity evaluation
por: Shintani, Tomohiro, et al.
Publicado: (2023)

UGT2B17 Genetic Polymorphisms Dramatically Affect the Pharmacokinetics of MK-7246 in Healthy Subjects in a First-in-Human Study
por: Wang, Y-H, et al.
Publicado: (2012)

Phenotyping of UGT1A1 Activity Using Raltegravir Predicts Pharmacokinetics and Toxicity of Irinotecan in FOLFIRI
por: Lee, Lawrence Soon-U, et al.
Publicado: (2016)

Isothiocyanates induce UGT1A1 in humanized UGT1 mice in a CAR dependent fashion that is highly dependent upon oxidative stress
por: Yoda, Emiko, et al.
Publicado: (2017)

The Effect of UGT1A1 Promoter Polymorphism in the Development of Hyperbilirubinemia and Cholelithiasis in Hemoglobinopathy Patients
por: AlFadhli, Suad, et al.
Publicado: (2013)

Association between UGT1A1 Polymorphism and Risk of Laryngeal Squamous Cell Carcinoma
por: Huangfu, Hui, et al.
Publicado: (2016)

Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer
por: Fujii, Hironori, et al.
Publicado: (2018)

The Activity of Members of the UDP-Glucuronosyltransferase Subfamilies UGT1A and UGT2B is Impaired in Patients with Liver Cirrhosis
por: Duthaler, Urs, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_l07eqg2pirllubte9ierh0cm29